A diagnosis of liver failure brings a profound sense of urgency and uncertainty. Whether it develops suddenly over days or gradually over years, the condition impacts every system in the body. Patients often grapple with extreme fatigue, confusion, fluid retention that makes movement difficult, and the distressing visible sign of jaundice. The liver is the body’s primary filtration and processing plant, so when it shuts down, toxins accumulate rapidly, threatening the brain and other organs. Treatment is critical to stabilize the body’s chemistry, prevent life-threatening swelling in the brain, and manage the underlying cause to give the liver a chance to regenerate or bridge the patient to a transplant. 

Because liver failure separates into acute (sudden onset) and chronic (end-stage liver disease) categories, treatment paths diverge significantly. Acute cases often require intensive care support immediately, whereas chronic failure involves long-term management of complications. Decisions regarding medication and hospitalization depend entirely on the speed of onset and the root cause, such as a viral infection, drug overdose, or autoimmune condition (American Liver Foundation, 2023). 

Overview of treatment options for Liver Failure 

The primary goal of treating liver failure is to keep the patient alive by performing the duties the liver can no longer handle. This involves stabilizing blood sugar, controlling bleeding risks, and removing toxins from the bloodstream. 

In acute liver failure, the priority is identifying the cause such as a toxin and reversing it if possible. In chronic liver failure, treatment focuses on managing complications like fluid buildup (ascites) and mental confusion (encephalopathy). While a liver transplant is the only cure for irreversible failure, medication protocols are essential to manage the patient’s condition while they await a donor or to support the liver’s natural ability to heal in reversible cases. 

Medications used for Liver Failure 

Doctors use specific combinations of drugs to target toxins, reduce fluid, and clear bacterial threats. 

Acetylcysteine is a critical first-line medication specifically for acute liver failure caused by acetaminophen overdose. If administered early enough, it can prevent severe liver damage. Clinical experience suggests that this medication is most effective when given within a few hours of ingestion, though it may still provide benefits in later stages of acute failure. 

Lactulose and antibiotics like rifaximin treat hepatic encephalopathy, a condition causing brain-related confusion or coma due to toxins. Lactulose, a syrup, clears toxins via the gut. These combined medications improve mental status and prevent recurrence. 

Diuretics like spironolactone and furosemide are standard treatments for chronic liver failure, managing ascites and edema. They remove excess fluid from the abdomen and legs, easing pressure and improving breathing. 

Vasoactive medications may be used in a hospital setting for patients with hepatorenal syndrome, a complication where liver failure stresses the kidneys. Drugs like midodrine or octreotide help improve blood flow to the kidneys. 

How these medications work 

The medications used for liver failure function by neutralizing toxins or altering fluid dynamics. 

Acetylcysteine works by replenishing glutathione, which the liver uses to neutralize toxic metabolic byproducts, thereby preventing liver cell death from toxic exposure. 

Lactulose traps ammonia, a toxic waste product, in the colon by changing gut acidity to convert ammonia into a non-absorbable form, then expels it as a laxative. Rifaximin aids this by reducing ammonia-producing gut bacteria. 

Diuretics signal the kidneys to filter excess sodium and water, reducing overall fluid volume. This lowers pressure in the liver’s veins, decreasing fluid leakage into the abdominal cavity. 

Side effects and safety considerations 

Treating liver failure requires balancing potent medications in a fragile system. Lactulose commonly causes GI side effects (gas, bloating, diarrhea); dosage is adjusted for specific daily bowel movements.  

Diuretics risk dehydration and electrolyte imbalances (low sodium/potassium), potentially straining kidneys or causing heart rhythm issues. Regular blood work is essential to monitor kidney function and electrolytes (National Institute of Diabetes and Digestive and Kidney Diseases, 2024). 

Due to the liver’s inability to process them, patients must avoid sedatives or pain medications unless closely monitored, as they can cause prolonged sedation. Seek immediate medical attention for signs of GI bleeding (e.g., vomiting blood) or increased confusion, which signal worsening liver failure. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. American Liver Foundation. https://liverfoundation.org 
  1. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. Merck Manuals. https://www.merckmanuals.com 

Medications for Liver Failure

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Liver Failure.

Found 7 Approved Drugs for Liver Failure

Lactulose

Brand Names
Kristalose, Enulose, Constulose, Generlac

Lactulose

Brand Names
Kristalose, Enulose, Constulose, Generlac
For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia level by 25 to 50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients’ protein tolerance is also frequently observed with lactulose solution therapy. In the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies.

Xifaxan

Generic Name
Rifaximin

Xifaxan

Generic Name
Rifaximin
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older.

Felbatol

Generic Name
Felbamate

Felbatol

Generic Name
Felbamate
Felbamate oral suspension is not indicated as a first line antiepileptic treatment. Felbamate oral suspension is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate oral suspension can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

Nefazodone

Generic Name
Nefazodone

Nefazodone

Generic Name
Nefazodone
Nefazodone hydrochloride tablets are indicated for the treatment of depression. When deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride treatment. In many cases, this would lead to the conclusion that other drugs should be tried first. The efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6 week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the DSM-III or DSM-IIIR category of major depressive disorder. A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). It must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of nefazodone in reducing relapse in patients with major depression who were judged to have had a satisfactory clinical response to 16 weeks of open-label nefazodone treatment for an acute depressive episode has been demonstrated in a randomized placebo-controlled trial. Although remitted patients were followed for as long as 36 weeks in the study cited (i.e., 52 weeks total), the physician who elects to use nefazodone for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.

Iqirvo

Generic Name
Elafibranor

Iqirvo

Generic Name
Elafibranor
IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). IQIRVO is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 ) Limitations of Use Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).
Showing 1-5 of 7
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances